By otakuyassine3@gmail.com 
Public Employees Retirement System of Ohio trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 4.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,892 shares of the biotechnology company’s stock after selling 1,638 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Sarepta Therapeutics were worth $4,108,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after purchasing an additional 543,143 shares during the period. Wellington Management Group LLP raised its stake in Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after buying an additional 665,087 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after buying an additional 63,437 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after buying an additional 37,940 shares during the period. Finally, Erste Asset Management GmbH purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter worth $79,425,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.
Wall Street Analysts Forecast Growth
SRPT has been the subject of a number of research reports. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective for the company. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday, November 27th. Raymond James reaffirmed an “outperform” rating and set a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $152.00 to $167.00 in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $178.71.
Sarepta Therapeutics Trading Down 0.6 %
SRPT stock opened at $123.71 on Monday. The firm has a fifty day moving average price of $123.12 and a 200 day moving average price of $131.53. Sarepta Therapeutics, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $173.25. The firm has a market cap of $11.82 billion, a PE ratio of 98.97 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.
Insider Buying and Selling at Sarepta Therapeutics
In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.70% of the stock is owned by company insiders.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report).
Receive News & Ratings for Sarepta Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.